86 related articles for article (PubMed ID: 7618043)
1. Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route.
Navarro JF; Teruel JL; Marcén R; Ortuño J
Scand J Urol Nephrol; 1995 Mar; 29(1):11-4. PubMed ID: 7618043
[TBL] [Abstract][Full Text] [Related]
2. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
Carlini R; Obialo CI; Rothstein M
Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
Marusza W; Matuszkiewicz-Rowińska J; Tomik Z; Andrzejewski A; Rokicka M; Paszkowska M; Drygieniec D; Bobilewicz D; Zawadzka M; Abbas-Fatah A
Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
[TBL] [Abstract][Full Text] [Related]
4. Comparison between intravenous recombinant human erythropoietin and subcutaneous injection in Thai hemodialysis patients.
Trakarnvanich T; Thitiarcharkul S
J Med Assoc Thai; 2004 Sep; 87(9):1041-7. PubMed ID: 15516004
[TBL] [Abstract][Full Text] [Related]
5. Association between erythropoietin requirements and antihypertensive agents.
Yano S; Suzuki K; Iwamoto M; Urushidani Y; Yokogi H; Kusakari M; Aoki A; Sumi M; Kitamura K; Sanematsu H; Gohbara M; Imamura S; Sugimoto T
Nephron Clin Pract; 2008; 109(1):c33-9. PubMed ID: 18506108
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
[TBL] [Abstract][Full Text] [Related]
7. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
Raja R; Bloom E; Johnson R; Goldstein M
Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin response and route of administration.
Taylor JE; Belch JJ; Fleming LW; Mactier RA; Henderson IS; Stewart WK
Clin Nephrol; 1994 May; 41(5):297-302. PubMed ID: 8050210
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
Abreo K; Lubom JA; Collier L; Fleming D; Work J
Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
[TBL] [Abstract][Full Text] [Related]
11. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
Allegra V; Martimbianco L; Vasile A
Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].
Ruedin P; Stoerman C; Pechère-Bertschi A; Leski M
Nephrologie; 1992; 13(2):87-92. PubMed ID: 1608502
[TBL] [Abstract][Full Text] [Related]
13. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
[TBL] [Abstract][Full Text] [Related]
14. Importance of iron supply for erythropoietin therapy.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin and cardiovascular risk.
Allegra V; Martimbianco L; Mengozzi G; Vasile A
Blood Purif; 1995; 13(6):301-13. PubMed ID: 8821194
[TBL] [Abstract][Full Text] [Related]
16. Once weekly subcutaneous administration of recombinant erythropoietin in children treated with CAPD.
Goldraich I; Goldraich N
Adv Perit Dial; 1992; 8():440-3. PubMed ID: 1361843
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
Raja R; Bloom E; Johnson R
Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
[TBL] [Abstract][Full Text] [Related]
18. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration.
Raymond CB; Collins DM; Bernstein KN; Skwarchuk DE; Vercaigne LM
Nephron Clin Pract; 2006; 102(3-4):c88-92. PubMed ID: 16282700
[TBL] [Abstract][Full Text] [Related]
20. RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy.
Schwartz AB; Kahn SB; Kelch B; Kim KE; Pequignot E
Clin Nephrol; 1992 Nov; 38(5):283-9. PubMed ID: 1451342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
